Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | CHIEF TECHNICAL OFFICER | June 14, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date June 14, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-06-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-14 · Exercise / conversion · Acquired 10,600 · Balance 10,600 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. Row 2 · 2024-06-14 · Sale · Disposed 10,600 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2032-03-20 | Direct | 68,800 |
Reported balance
After 2024-06-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-14 · Exercise / conversion · Disposed 10,600 · Balance 68,800 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F2: 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023.
F2: 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,600 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0001415889-24-016994 · form4-06142024_060603.xml · derivative · entry 3 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,800 Underlying: Common Stock · 10,600 shares Expires 2032-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,600 | $25.00 | $265,000.00 |
DisclosureSEC source: 0001415889-24-016994 · form4-06142024_060603.xml · nonDerivative · entry 2 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,600 | $14.59 | $154,654.00 |
DisclosureSEC source: 0001415889-24-016994 · form4-06142024_060603.xml · nonDerivative · entry 1 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,981 | $21.02 | $41,630.72 |
DisclosureSEC source: 0001415889-24-012235 · form4-05032024_060504.xml · nonDerivative · entry 1 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022. F2 · shares: Includes 1,981 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.972 to $21.12, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0001415889-24-010139 · form4-04032024_060410.xml · derivative · entry 4 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,400 Underlying: Common Stock · 5,300 shares Expires 2032-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,504 | $30.00 | $45,118.50 |
DisclosureSEC source: 0001415889-24-010139 · form4-04032024_060410.xml · nonDerivative · entry 3 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.65 to $30.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,796 | $28.87 | $109,578.75 |
DisclosureSEC source: 0001415889-24-010139 · form4-04032024_060410.xml · nonDerivative · entry 2 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,504 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.475 to $29.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 5,300 | $14.59 | $77,327.00 |
DisclosureSEC source: 0001415889-24-010139 · form4-04032024_060410.xml · nonDerivative · entry 1 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0001415889-24-008772 · form4-03202024_060317.xml · derivative · entry 4 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,700 Underlying: Common Stock · 5,300 shares Expires 2032-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,764 | $26.46 | $73,123.83 |
DisclosureSEC source: 0001415889-24-008772 · form4-03202024_060317.xml · nonDerivative · entry 3 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.30 to $26.71, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,536 | $25.68 | $65,119.15 |
DisclosureSEC source: 0001415889-24-008772 · form4-03202024_060317.xml · nonDerivative · entry 2 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,764 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.255 to $26.125, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 5,300 | $14.59 | $77,327.00 |
DisclosureSEC source: 0001415889-24-008772 · form4-03202024_060317.xml · nonDerivative · entry 1 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 66,586 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001776 · form4-01242024_060108.xml · derivative · entry 1 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,586 Underlying: Common Stock · 66,586 shares Expires 2034-01-21 F1 · derivative.exercise_date: The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 970 | $10.46 | $10,148.63 |
DisclosureSEC source: 0001415889-23-014774 · form4-11032023_051106.xml · nonDerivative · entry 1 Verwijs Marinus · CIK 0001916553 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022. F2 · shares: Includes 970 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.96 to $10.78, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 03, 2023 Filed May 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 759 | $20.79 | $15,779.38 |
DisclosureSEC source: 0001415889-23-007476 · form4-05052023_060501.xml · nonDerivative · entry 1 Verwijs Marinus · CIK 0001916553 · SENIOR VICE PRESIDENT, CMC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022. F2 · shares: Includes 759 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.78 to $20.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 23:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $25.57 | $0.00 |
DisclosureSEC source: 0001415889-23-002174 · form4-02082023_060211.xml · derivative · entry 1 Verwijs Marinus · CIK 0001916553 · SENIOR VICE PRESIDENT, CMC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on March 7, 2023. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 21:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,130 | $18.89 | $21,345.70 |
DisclosureSEC source: 0001415889-22-011066 · form4-11032022_051101.xml · nonDerivative · entry 1 Verwijs Marinus · CIK 0001916553 · SENIOR VICE PRESIDENT, CMC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022. F2 · shares: Includes 1,130 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 11:47 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0001493152-22-007499 · ownership.xml · derivative · entry 1 Verwijs Marinus · CIK 0001916553 · Senior Vice President, CMC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-03-20 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.